Trevogrumab

1. Trevogrumab decreases lean mass loss in humans (-2.8% to -4.0% vs -5.9% to -7.1%).

   “there was significantly less LM loss in the trevo 200mg, 400mg, and triplet groups vs sema alone”

   Human trialwith or without low lean mass at baseline200mg or 400mg + semaglutide 2.4mg26 weeksn = 599

   Lean Mass Effects of Anti-GDF8 (Trevogrumab) ± Anti-Activin A (Garetosmab) in People Living with Obesity Treated with Semaglutide with or without Low Lean Mass at Baseline

   ADA Scientific Sessions 2026 abstract·7 Jun 2026

1. Trevogrumab decreases total fat mass z-score in humans.

   “Statistical significance (CFB vs semaglutide alone) was met for TLM and TFM z-scores for all trevogrumab groups with and without garetosmab”

   Human trialwith or without garetosmab, on top of semaglutideweek 26n = 599

   Population-Normed Z-scores for Body Composition Enhance Sensitivity and Effect Size: Analysis of a Phase 2 RCT Testing Anti-GDF8 and Anti-Activin A on Top of Semaglutide (COURAGE)

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Total fat mass z-score

1. Trevogrumab increases total lean mass z-score in humans.

   “Statistical significance (CFB vs semaglutide alone) was met for TLM and TFM z-scores for all trevogrumab groups with and without garetosmab”

   Human trialwith or without garetosmab, on top of semaglutideweek 26n = 599

   Population-Normed Z-scores for Body Composition Enhance Sensitivity and Effect Size: Analysis of a Phase 2 RCT Testing Anti-GDF8 and Anti-Activin A on Top of Semaglutide (COURAGE)

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Total lean mass z-score